key: cord-1002593-nfu0wcz6
authors: Mukerji, Shibani S.; Solomon, Isaac H.
title: What can we learn from brain autopsy in COVID-19?
date: 2020-11-25
journal: Neurosci Lett
DOI: 10.1016/j.neulet.2020.135528
sha: 9f49332ddd9aca7ce60d7d73e9b0fb981e7528b4
doc_id: 1002593
cord_uid: nfu0wcz6

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) for which there have been over 50 million confirmed cases and 1.2 million deaths globally. While many SARS-CoV-2 infected individuals are asymptomatic or experience respiratory symptoms, extrapulmonary manifestations, including neurological symptoms and conditions, are increasingly recognized. There remains no clear understanding of the mechanisms that underlie neurological symptoms in COVID-19 and whether SARS-CoV-2 has the potential for neuroinvasion in humans. In this minireview, we discuss what is known from human autopsies in fatal COVID-19, including highlighting studies that investigate for the presence of SARS-CoV-2 in brain and olfactory tissue, and summarize the neuropathological consequences of infection. Incorporating microscopic and molecular findings from brain tissue into what we know about clinical disease will inform best practice management guidance and direct research priorities as it relates to neurological morbidity from COVID-19.

different databases (PubMed, Google Scholar) were searched for key terms, including COVID-19, nCoV-2019, and SARS-CoV-2, crossed with autopsy, histology, histopathology, neuropathology, and post-mortem. This search was complemented with three review articles [22] [23] [24] , text word searching and examining references in identified articles. A total of 24 studies were identified that included 149 individuals (range 1-43 subjects per series).

Reported gross and microscopic findings and results of SARS-CoV-2 targeted studies are summarized in Table 1 .

Representative gross, microscopic, and ultrastructural findings are illustrated in Figure 1 .

Gross brain autopsy findings were reported individually or in aggregate for 142 subjects. In keeping with the high prevalence of comorbidities in this patient population, evidence of prior brain disease was frequently identified, including neurodegeneration, prior strokes, tumor resection, demyelinating disease, and atherosclerosis.

Acute gross abnormalities were much more limited, and a direct causal relationship with SARS-CoV-2 infection was not always straightforward to identify. A total of 92 (65%) of the gross brain examinations reported either no significant findings or no acute abnormalities. Of the remaining 50 cases, multiple findings were often described in individual brains. Hemorrhage was the most common abnormality reported, ranging from petechial bleedings and punctate subarachnoid hemorrhages (n=9) [14, [27] [28] [29] [30] [31] , to large cerebral/cerebellar hemorrhages (n=4) [27, 32, 33] , hemorrhagic conversion of middle cerebral artery stroke (n=1) [34] , and a recently drained subdural hematoma (n=1) [32] . Large acute and/or subacute infarcts (n=11) [29, 31, 33, 35] as well as lacunar infarcts/microinfarcts and watershed infarcts (n=2) [29, 30] were identified in several cases. Severe edema resulting in herniation (n=5) [27, 31, 33] as well as mild to moderate edema without herniation (n=34) [14, 30, 31, 35, 36] were also present.

Microscopic findings were reported for 146 of the cases in these studies. Similar to the gross examinations, histopathology identified correlates of pre-existing disease, including neurodegeneration, chronic/subacute s trokes, hepatic encephalopathy, and arteriolosclerosis. No specific findings were reported for 25 (17%) of the cases. Mild to moderate acute hypoxic injury was the most common abnormality (n=58) [14, 27, 30, 31, 33, 34, [36] [37] [38] , while severe hypoxic-ischemic injury (n=1) [36] and infarcts/focal ischemic necrosis (n=22) [14, 29, 31, 32, 35] were identified in several cases. Focal microhemorrhage or hemorrhagic suffusion was also frequently reported (n=23) [14, [28] [29] [30] [31] [32] [33] , although intravascular microthrombi (n=12) [31, 39] or neutrophilic plugs (n=3) [38] were less common. Mild focal perivascular, parenchymal, and leptomeningeal T-cell predominant lymphocytic infiltrates were identified in a large number of cases without clear evidence of vasculitis or meningoencephalitis (n=81) [27, [29] [30] [31] [33] [34] [35] [36] [37] [38] [39] . Moderate to intense microglial activation was noted, particularly in the brainstem (n=73), although similar results were also J o u r n a l P r e -p r o o f reported in COVID-19-negative individuals with systemic inflammatory/septic clinical courses [31, [33] [34] [35] [36] 38] .

Axonal damage was identified in a few cases (n=5) [14, 27, 30] . Acute disseminated encephalomyelitis (ADEM)-like lesions were reported in a single case [14] . The olfactory system was examined to varying degrees, identifying prominent acute and chronic inflammation in the olfactory epithelium (n=14) [33, 38, 39] , microglial activation (n=18) [36] and red neurons (n=1) [44] in the olfactory bulb, and only unremarkable age-related corpora amylacea in olfactory tracts.

Researchers across the globe have employed multiple strategies to directly assess for the presence of SARS-CoV-2 in brain tissue, including immunohistochemistry, in situ hybridization (ISH), targeted quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and transmission electron microscopy. At this time, immunohistochemistry, using antibodies that recognize the viral nucleocapsid (N) or spike (S) proteins, have been negative in most attempted human cases (n=58) [30, 33, 35, 37, 38] , with the exception of a recent case series that reported positive staining in vagus and glossopharyngeal nerves and scattered cells in the medulla in a total of 16 cases [35] ; in situ hybridization for viral RNA has been negative (n=1) [38] . Viral spike protein has been reported to be present in the olfactory epithelium in 5/6 patients; however, brain findings from these cases were not discussed [40] . A number of qRT-PCR assays have been employed targeting the N, S, envelope (E), open reading frame (ORF) 1/a, ORF1ab, or RNA-dependent reverse transcriptase (RdRp) genes, identifying low levels of virus in frozen or formalin-fixed paraffin-embedded brain tissue (34/84; 41%) [12, [30] [31] [32] [33] [34] [35] [36] [37] 41] and olfactory bulb/tract (n=9/36; 25%) [31, 33, 36, 37] . Viral subgenomic RNA, a marker of actively replicating virus, was positive in a single case (n=1/5; 20%) [43, 44] . Transmission electron microscopy (TEM) without immunolabeling reported virus-like particles in the frontal lobe (n=1) [45] .

While additional COVID-19 autopsy series continue to be published, the overall picture of acute hypoxicinjury, hemorrhage, and mild to moderate non-specific inflammation is unlikely to change significantly. Evidence of direct viral involvement in the brain or olfactory nerve is limited to the detection of low levels of viral RNA and rare viral antigen in cranial nerves and scattered brainstem cells. Diagnosis of coronavirus particles by electron microscopy is challenging due to similar appearing normal cellular structures, which has created significant controversy in the literature [42, 43] . Due to the inherent bias of autopsy studies for severe, fatal disease, and additional institutional restrictions for which cases include brain evaluation, the frequency and extent of neuropathological findings are likely to be overestimated relative to the average COVID-19 patient. At the time of J o u r n a l P r e -p r o o f this review, pediatric autopsies, including individuals with multisystem inflammatory syndrome in children (MIS-C), remain extremely limited. While the number of pediatric COVID-19 cases accounts for <2% of all cases [44] , data obtained from brain tissue in this age-group can help address the unique pathophysiology of SARS-CoV-2 infection, including age-dependent immune-responses, hypercoagulability, and degree of hypoxic-ischemic injury.

Additional remaining areas of interest include characterizing the effects of remdesivir and other potential antiviral therapeutics, immunomodulatory medications including dexamethasone, anti-IL-6 or other monoclonal antibodies, and anticoagulants on brain tissue. Given that the therapeutic response to COVID-19 vastly differs between institutions, it remains a challenge to understand how therapeutic choices during acute hospitalization are responsible for the variability in observed neurological manifestations and neuropathological findings. Also, while not surprisingly this early in the pandemic, long-term neuropathological sequelae in COVID-19 survivors remain unstudied. There is evidence that neurological symptoms, including fatigue and headaches, linger for weeks to months in a subset of affected patients [45, 46] and studies determining mechanisms for persistent neurological symptoms are needed.

There have been several efforts for sharing COVID-19 brain tissue, including the International Society of Neuropathology (ISN) Collaborative Efforts [47] and the COVID-19 Virtual Biobank at the University of Nebraska Medical Center [48] . To address many of the remaining unanswered questions regarding the neuropathological effects of COVID-19, large scale integrated studies from multiple institutions with relevant clinical metadata will be crucial. The ongoing collection of neurological tissue will be critical to inform best practice management guidance and to direct research priorities as it relates to neurological morbidity from COVID-19. 

COVID-19 map-Johns Hopkins Coronavirus Resource Center

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

ISARIC4C investigators, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Extrapulmonary manifestations of COVID-19

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review

Neurological associations of COVID-19

Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza

Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study

COVID-19 and the Chemical Senses: Supporting Players Take Center Stage

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Encephalitis Associated with COVID-19 Infection in an 11-Year-Old Child

Others, Steroid-responsive encephalitis in Covid-19 disease

Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review

Changes in rates of autopsy-detected diagnostic errors over time: a systematic review

Clinical-Forensic Autopsy Findings to Defeat COVID-19 Disease: A Literature Review

A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression

Histopathological observations in COVID-19: a systematic review

Autopsy in suspected COVID-19 cases

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Early evidence of pronounced brain involvement in fatal COVID-19 outcomes

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19

Neuropathologic features of four autopsied COVID-19 patients

Brain ischemic injury in COVID-19-infected patients: a series of 10 post-mortem cases

Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients

Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a postmortem study

Neuropathology of J o u r n a l P r e -p r o o f patients with COVID-19 in Germany: a post-mortem case series

Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology

Neuropathological Features of Covid-19

Inflammatory olfactory neuropathy in two patients with COVID-19

Neuropilin -1 facilitates SARS-CoV-2 cell entry and infectivity

Multiorgan and Renal Tropism of SARS-CoV-2

Visualization of putative coronavirus in kidney

Caution in Identifying Coronaviruses by Electron Microscopy

Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group, Children with Covid-19 in Pediatric Emergency Departments in Italy

Gemelli Against COVID-19 Post-Acute Care Study Group, Persistent Symptoms in Patients After Acute COVID-19

IVY Network Investigators, CDC COVID-19 Response Team, IVY Network Investigators, Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States

COVID-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Postmortem Examination of Patients With COVID-19

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology

COVID-19 Autopsies

Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c)

SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective

We would like to acknowledge all front-line healthcare workers taking care of patients during the COVID-19 pandemic, and patients and their families who contribute research to help understand neurological disease.

J o u r n a l P r e -p r o o f 

Puelles et al. 2020 [41] Wichmann et. al. 2020 [49] Matschke et al. 2020 [35] 43; subset full autopsy with brain findings Edema (n=23), fresh territorial infarct (n=6)Fresh ischemic infarct (n=6), astrocytosis, microgliosis, perivascular, parenchymal, and leptomeningeal T cells (n=43)qRT-PCR positive (